MET and non-small cell lung carcinoma: The clinical relevance of c-Met inhibitors is now under investigation, phase II and III clinical trials in a variety of malignancies including non-small cell lung cancer [20–22], colorectal cancer [23], gastroesophageal cancer [24] are ongoing.